HR
UTHR icon

Howe & Rusling’s United Therapeutics UTHR Stock Holding History

Howe & Rusling’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-20
Closed -$2K – 879
2019
Q4 		$2K Hold
20
– – ﹤0.01% 703
2019
Q3 		$2K Buy
+20
New +$1.61K ﹤0.01% 716
2015
Q4 		– Sell
-30
Closed -$4K – 1074
2015
Q3 		$4K Hold
30
– – ﹤0.01% 693
2015
Q2 		$5K Sell
30
-16
-35% -$2.88K ﹤0.01% 662
2015
Q1 		$8K Sell
46
-18
-28% -$2.74K ﹤0.01% 540
2014
Q4 		$8K Buy
+64
New +$8.25K ﹤0.01% 548

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Howe & Rusling's UTHR Position: Q1 2020 in Review

Howe & Rusling sold out of United Therapeutics (UTHR) in Q1 2020, closing a stake of 20 shares — an estimated $2K sold.

Howe & Rusling first reported a position in UTHR in Q4 2014 and held it in 6 quarters. The position peaked at $8K in Q1 2015. 303 funds tracked by Wall St. Rank hold UTHR as of Q1 2020.

  • Howe & Rusling reported no remaining United Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Howe & Rusling sold 20 United Therapeutics shares in Q1 2020, an estimated $2K.
  • Howe & Rusling first reported a position in United Therapeutics in Q4 2014 and held it in 6 quarters.
  • Howe & Rusling's United Therapeutics position peaked at $8K in Q1 2015.
  • 303 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2020.

Based on Howe & Rusling's 13F filing for Q1 2020, filed 14 May 2020.